Cefpiramide sodium (CAS 74849-93-7)

Cefpiramide sodium, a third-generation cephalosporin antibiotic, has garnered significant attention in scientific research due to its potent antibacterial properties and unique mechanism of action against a wide range of Gram-positive and Gram-negative bacteria. It functions by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to the disruption of peptidoglycan cross-linking and eventual cell lysis. Research on cefpiramide sodium has focused on elucidating its spectrum of activity and potency against clinically relevant pathogens, including multi-drug resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Moreover, studies have investigated its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, to optimize dosing regimens and outcomes. Additionally, cefpiramide sodium has been utilized in research exploring combination therapy strategies and synergistic interactions with other antimicrobial agents to enhance efficacy and combat antibiotic resistance. Furthermore, ongoing investigations aim to develop novel formulations and delivery systems for cefpiramide sodium to improve bioavailability and tissue penetration, thereby maximizing its potential. Overall, cefpiramide sodium serves as a valuable tool in research endeavors aimed at understanding bacterial pathogenesis, antibiotic resistance mechanisms, and the development of innovative approaches to combat infectious diseases.